A very early clinical response to treatment with the Janus kinase inhibitor tofacitinib in patients with active rheumatoid arthritis: the dynamics of pain and central sensitization elements
Janus kinase (JK) inhibitors block the intracellular signaling pathways that are responsible for the synthesis of proinflammatory cytokines and mediators, which in turn cause the activation of pain receptors and central sensitization (CS). It is suggested that JK inhibitors can rapidly eliminate pai...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2020-05-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/1010 |
| _version_ | 1797876692631420928 |
|---|---|
| author | A. E. Karateev E. S. Filatova E. Yu. Pogozheva V. N. Amirdzhanova E. L. Nasonov A. M. Lila V. I. Mazurov A. Yu. De A. A. Baranov N. A. Lapkina G. V. Lukina N. A. Kiryukhina S. Yu. Davidyan T. S. Salnikova R. R. Samigullina D. S. Chakieva I. M. Marusenko O. V. Semagina M. Yu. Semchenkova A. F. Davydova E. V. Kalinina |
| author_facet | A. E. Karateev E. S. Filatova E. Yu. Pogozheva V. N. Amirdzhanova E. L. Nasonov A. M. Lila V. I. Mazurov A. Yu. De A. A. Baranov N. A. Lapkina G. V. Lukina N. A. Kiryukhina S. Yu. Davidyan T. S. Salnikova R. R. Samigullina D. S. Chakieva I. M. Marusenko O. V. Semagina M. Yu. Semchenkova A. F. Davydova E. V. Kalinina |
| author_sort | A. E. Karateev |
| collection | DOAJ |
| description | Janus kinase (JK) inhibitors block the intracellular signaling pathways that are responsible for the synthesis of proinflammatory cytokines and mediators, which in turn cause the activation of pain receptors and central sensitization (CS). It is suggested that JK inhibitors can rapidly eliminate pain and reduce the severity of CS.Objective: to evaluate the effect of the JK inhibitor tofacitinib (TOFA) on the intensity of pain and the signs of CS in patients with active rheumatoid arthritis (RA) at 7 and 28 days after therapy initiation.Patients and methods. A study group consisted of 39 patients (79.5% female) (mean age 50.9±11.1 years) with RA (DAS28 5.8±0.6). Of these, 89.7% were seropositive for rheumatoid factor; 82.0% took methotrexate and 18.0% received leflunomide. All the patients were prescribed TOFA 5 mg twice daily due to the inefficacy or intolerance of biological agents. The investigators estimated pain intensity using a Brief Pain Inventory (BPI), rated the presence of a neuropathic pain component (NPC) with the PainDETECT questionnaire, and assessed the signs of CS with the Central Sensitization Inventory (CSI) during the first 4 weeks after TOFA administration.Results and discussion. The patients initially experienced moderate or severe pain (the mean scores of 5.33±2.51 on the numerical rating scale (NRS) included in BPI); 53.8% had signs of CS (CSI scores of ≥40); 17.9% had signs of a NPC (PainDETECT scores of >18). Already on day 7 after the start of TOFA administration, there was a statistically significant decrease in the mean NRS pain intensity scores to 4.06±2.2 (p=0.01) and by 29.4±17.9%, as shown by the patient's assessment of the analgesic effect of therapy (BPI), as well as the severity of CS, namely a decrease in the mean NRS pain score to 35.9±11.2 (p=0.01). On 28 days, the effect became better: there was a reduction in the level of NRS pain to 2.32±1.57 (p<0.001), in pain according to the patient's assessment of the analgesic effect of therapy to 43.6±29.6%; in the median PainDETECT score to 2.5 [0; 8.7] (p<0.001); and in CSI scores to an average of 26.4±13.9 (p <0.001). No serious adverse reactions were noted.TOFA has a rapid analgesic effect, which allows it to be considered as a chooser for pathogenetic therapy in patients with active RA and severe pain, especially in the presence of CS signs and secondary fibromyalgia. Undoubtedly, large-scale, long-term controlled studies with a wider range of estimated parameters are required to clarify the therapeutic potential of TOFA in this patient category. The limitation of this investigation was its open observer design pattern.Conclusion. The use of the JK inhibitor TOFA can achieve a rapid analgesic effect, inter alia due to its effect on CS and NPC. |
| first_indexed | 2024-04-10T02:06:39Z |
| format | Article |
| id | doaj.art-af84c1d6e4e34c688e41f9ab87acd8f6 |
| institution | Directory Open Access Journal |
| issn | 1996-7012 2310-158X |
| language | Russian |
| last_indexed | 2024-04-10T02:06:39Z |
| publishDate | 2020-05-01 |
| publisher | IMA-PRESS LLC |
| record_format | Article |
| series | Современная ревматология |
| spelling | doaj.art-af84c1d6e4e34c688e41f9ab87acd8f62023-03-13T08:39:27ZrusIMA-PRESS LLCСовременная ревматология1996-70122310-158X2020-05-01142697510.14412/1996-7012-2020-2-69-752251A very early clinical response to treatment with the Janus kinase inhibitor tofacitinib in patients with active rheumatoid arthritis: the dynamics of pain and central sensitization elementsA. E. Karateev0E. S. Filatova1E. Yu. Pogozheva2V. N. Amirdzhanova3E. L. Nasonov4A. M. Lila5V. I. Mazurov6A. Yu. De7A. A. Baranov8N. A. Lapkina9G. V. Lukina10N. A. Kiryukhina11S. Yu. Davidyan12T. S. Salnikova13R. R. Samigullina14D. S. Chakieva15I. M. Marusenko16O. V. Semagina17M. Yu. Semchenkova18A. F. Davydova19E. V. Kalinina20ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииФГБОУ ВО «Северо-Западный государственный медицинский университет им. И.И. Мечникова» Минздрава РоссииФГБОУ ВО «Северо-Западный государственный медицинский университет им. И.И. Мечникова» Минздрава РоссииФГБОУ ВО «Ярославский государственный медицинский университет» Минздрава РоссииФГБОУ ВО «Ярославский государственный медицинский университет» Минздрава РоссииГБУЗ г. Москвы «Московский клинический научно-практический центр им. А.С. Логинова» Департамента здравоохранения г. МосквыФГБУ «Национальный медико-хирургический центр им. Н.И. Пирогова» Минздрава РоссииФГБУ «Национальный медико-хирургический центр им. Н.И. Пирогова» Минздрава РоссииГУЗ Тульской области «Тульская областная клиническая больница»ФГБОУ ВО «Северо-Западный государственный медицинский университет им. И.И. Мечникова» Минздрава РоссииФГБОУ ВО «Северо-Западный государственный медицинский университет им. И.И. Мечникова» Минздрава РоссииФГБОУ ВО «Петрозаводский государственный университет» Минобрнауки РоссииГБУЗ «Самарская областная клиническая больница им. В.Д. Середавина»ФГБОУ ВО «Смоленский государственный медицинский университет» Минздрава РоссииГБУЗ «Научно-исследовательский институт – Краевая клиническая больница №1 им. проф. С.В. Очаповского»ФГБОУ ВО «Волгоградский государственный медицинский университет» Минздрава РоссииJanus kinase (JK) inhibitors block the intracellular signaling pathways that are responsible for the synthesis of proinflammatory cytokines and mediators, which in turn cause the activation of pain receptors and central sensitization (CS). It is suggested that JK inhibitors can rapidly eliminate pain and reduce the severity of CS.Objective: to evaluate the effect of the JK inhibitor tofacitinib (TOFA) on the intensity of pain and the signs of CS in patients with active rheumatoid arthritis (RA) at 7 and 28 days after therapy initiation.Patients and methods. A study group consisted of 39 patients (79.5% female) (mean age 50.9±11.1 years) with RA (DAS28 5.8±0.6). Of these, 89.7% were seropositive for rheumatoid factor; 82.0% took methotrexate and 18.0% received leflunomide. All the patients were prescribed TOFA 5 mg twice daily due to the inefficacy or intolerance of biological agents. The investigators estimated pain intensity using a Brief Pain Inventory (BPI), rated the presence of a neuropathic pain component (NPC) with the PainDETECT questionnaire, and assessed the signs of CS with the Central Sensitization Inventory (CSI) during the first 4 weeks after TOFA administration.Results and discussion. The patients initially experienced moderate or severe pain (the mean scores of 5.33±2.51 on the numerical rating scale (NRS) included in BPI); 53.8% had signs of CS (CSI scores of ≥40); 17.9% had signs of a NPC (PainDETECT scores of >18). Already on day 7 after the start of TOFA administration, there was a statistically significant decrease in the mean NRS pain intensity scores to 4.06±2.2 (p=0.01) and by 29.4±17.9%, as shown by the patient's assessment of the analgesic effect of therapy (BPI), as well as the severity of CS, namely a decrease in the mean NRS pain score to 35.9±11.2 (p=0.01). On 28 days, the effect became better: there was a reduction in the level of NRS pain to 2.32±1.57 (p<0.001), in pain according to the patient's assessment of the analgesic effect of therapy to 43.6±29.6%; in the median PainDETECT score to 2.5 [0; 8.7] (p<0.001); and in CSI scores to an average of 26.4±13.9 (p <0.001). No serious adverse reactions were noted.TOFA has a rapid analgesic effect, which allows it to be considered as a chooser for pathogenetic therapy in patients with active RA and severe pain, especially in the presence of CS signs and secondary fibromyalgia. Undoubtedly, large-scale, long-term controlled studies with a wider range of estimated parameters are required to clarify the therapeutic potential of TOFA in this patient category. The limitation of this investigation was its open observer design pattern.Conclusion. The use of the JK inhibitor TOFA can achieve a rapid analgesic effect, inter alia due to its effect on CS and NPC.https://mrj.ima-press.net/mrj/article/view/1010ревматоидный артритхроническая больцентральная сенситизациятофацитинибэффективностьбезопасность |
| spellingShingle | A. E. Karateev E. S. Filatova E. Yu. Pogozheva V. N. Amirdzhanova E. L. Nasonov A. M. Lila V. I. Mazurov A. Yu. De A. A. Baranov N. A. Lapkina G. V. Lukina N. A. Kiryukhina S. Yu. Davidyan T. S. Salnikova R. R. Samigullina D. S. Chakieva I. M. Marusenko O. V. Semagina M. Yu. Semchenkova A. F. Davydova E. V. Kalinina A very early clinical response to treatment with the Janus kinase inhibitor tofacitinib in patients with active rheumatoid arthritis: the dynamics of pain and central sensitization elements Современная ревматология ревматоидный артрит хроническая боль центральная сенситизация тофацитиниб эффективность безопасность |
| title | A very early clinical response to treatment with the Janus kinase inhibitor tofacitinib in patients with active rheumatoid arthritis: the dynamics of pain and central sensitization elements |
| title_full | A very early clinical response to treatment with the Janus kinase inhibitor tofacitinib in patients with active rheumatoid arthritis: the dynamics of pain and central sensitization elements |
| title_fullStr | A very early clinical response to treatment with the Janus kinase inhibitor tofacitinib in patients with active rheumatoid arthritis: the dynamics of pain and central sensitization elements |
| title_full_unstemmed | A very early clinical response to treatment with the Janus kinase inhibitor tofacitinib in patients with active rheumatoid arthritis: the dynamics of pain and central sensitization elements |
| title_short | A very early clinical response to treatment with the Janus kinase inhibitor tofacitinib in patients with active rheumatoid arthritis: the dynamics of pain and central sensitization elements |
| title_sort | very early clinical response to treatment with the janus kinase inhibitor tofacitinib in patients with active rheumatoid arthritis the dynamics of pain and central sensitization elements |
| topic | ревматоидный артрит хроническая боль центральная сенситизация тофацитиниб эффективность безопасность |
| url | https://mrj.ima-press.net/mrj/article/view/1010 |
| work_keys_str_mv | AT aekarateev averyearlyclinicalresponsetotreatmentwiththejanuskinaseinhibitortofacitinibinpatientswithactiverheumatoidarthritisthedynamicsofpainandcentralsensitizationelements AT esfilatova averyearlyclinicalresponsetotreatmentwiththejanuskinaseinhibitortofacitinibinpatientswithactiverheumatoidarthritisthedynamicsofpainandcentralsensitizationelements AT eyupogozheva averyearlyclinicalresponsetotreatmentwiththejanuskinaseinhibitortofacitinibinpatientswithactiverheumatoidarthritisthedynamicsofpainandcentralsensitizationelements AT vnamirdzhanova averyearlyclinicalresponsetotreatmentwiththejanuskinaseinhibitortofacitinibinpatientswithactiverheumatoidarthritisthedynamicsofpainandcentralsensitizationelements AT elnasonov averyearlyclinicalresponsetotreatmentwiththejanuskinaseinhibitortofacitinibinpatientswithactiverheumatoidarthritisthedynamicsofpainandcentralsensitizationelements AT amlila averyearlyclinicalresponsetotreatmentwiththejanuskinaseinhibitortofacitinibinpatientswithactiverheumatoidarthritisthedynamicsofpainandcentralsensitizationelements AT vimazurov averyearlyclinicalresponsetotreatmentwiththejanuskinaseinhibitortofacitinibinpatientswithactiverheumatoidarthritisthedynamicsofpainandcentralsensitizationelements AT ayude averyearlyclinicalresponsetotreatmentwiththejanuskinaseinhibitortofacitinibinpatientswithactiverheumatoidarthritisthedynamicsofpainandcentralsensitizationelements AT aabaranov averyearlyclinicalresponsetotreatmentwiththejanuskinaseinhibitortofacitinibinpatientswithactiverheumatoidarthritisthedynamicsofpainandcentralsensitizationelements AT nalapkina averyearlyclinicalresponsetotreatmentwiththejanuskinaseinhibitortofacitinibinpatientswithactiverheumatoidarthritisthedynamicsofpainandcentralsensitizationelements AT gvlukina averyearlyclinicalresponsetotreatmentwiththejanuskinaseinhibitortofacitinibinpatientswithactiverheumatoidarthritisthedynamicsofpainandcentralsensitizationelements AT nakiryukhina averyearlyclinicalresponsetotreatmentwiththejanuskinaseinhibitortofacitinibinpatientswithactiverheumatoidarthritisthedynamicsofpainandcentralsensitizationelements AT syudavidyan averyearlyclinicalresponsetotreatmentwiththejanuskinaseinhibitortofacitinibinpatientswithactiverheumatoidarthritisthedynamicsofpainandcentralsensitizationelements AT tssalnikova averyearlyclinicalresponsetotreatmentwiththejanuskinaseinhibitortofacitinibinpatientswithactiverheumatoidarthritisthedynamicsofpainandcentralsensitizationelements AT rrsamigullina averyearlyclinicalresponsetotreatmentwiththejanuskinaseinhibitortofacitinibinpatientswithactiverheumatoidarthritisthedynamicsofpainandcentralsensitizationelements AT dschakieva averyearlyclinicalresponsetotreatmentwiththejanuskinaseinhibitortofacitinibinpatientswithactiverheumatoidarthritisthedynamicsofpainandcentralsensitizationelements AT immarusenko averyearlyclinicalresponsetotreatmentwiththejanuskinaseinhibitortofacitinibinpatientswithactiverheumatoidarthritisthedynamicsofpainandcentralsensitizationelements AT ovsemagina averyearlyclinicalresponsetotreatmentwiththejanuskinaseinhibitortofacitinibinpatientswithactiverheumatoidarthritisthedynamicsofpainandcentralsensitizationelements AT myusemchenkova averyearlyclinicalresponsetotreatmentwiththejanuskinaseinhibitortofacitinibinpatientswithactiverheumatoidarthritisthedynamicsofpainandcentralsensitizationelements AT afdavydova averyearlyclinicalresponsetotreatmentwiththejanuskinaseinhibitortofacitinibinpatientswithactiverheumatoidarthritisthedynamicsofpainandcentralsensitizationelements AT evkalinina averyearlyclinicalresponsetotreatmentwiththejanuskinaseinhibitortofacitinibinpatientswithactiverheumatoidarthritisthedynamicsofpainandcentralsensitizationelements AT aekarateev veryearlyclinicalresponsetotreatmentwiththejanuskinaseinhibitortofacitinibinpatientswithactiverheumatoidarthritisthedynamicsofpainandcentralsensitizationelements AT esfilatova veryearlyclinicalresponsetotreatmentwiththejanuskinaseinhibitortofacitinibinpatientswithactiverheumatoidarthritisthedynamicsofpainandcentralsensitizationelements AT eyupogozheva veryearlyclinicalresponsetotreatmentwiththejanuskinaseinhibitortofacitinibinpatientswithactiverheumatoidarthritisthedynamicsofpainandcentralsensitizationelements AT vnamirdzhanova veryearlyclinicalresponsetotreatmentwiththejanuskinaseinhibitortofacitinibinpatientswithactiverheumatoidarthritisthedynamicsofpainandcentralsensitizationelements AT elnasonov veryearlyclinicalresponsetotreatmentwiththejanuskinaseinhibitortofacitinibinpatientswithactiverheumatoidarthritisthedynamicsofpainandcentralsensitizationelements AT amlila veryearlyclinicalresponsetotreatmentwiththejanuskinaseinhibitortofacitinibinpatientswithactiverheumatoidarthritisthedynamicsofpainandcentralsensitizationelements AT vimazurov veryearlyclinicalresponsetotreatmentwiththejanuskinaseinhibitortofacitinibinpatientswithactiverheumatoidarthritisthedynamicsofpainandcentralsensitizationelements AT ayude veryearlyclinicalresponsetotreatmentwiththejanuskinaseinhibitortofacitinibinpatientswithactiverheumatoidarthritisthedynamicsofpainandcentralsensitizationelements AT aabaranov veryearlyclinicalresponsetotreatmentwiththejanuskinaseinhibitortofacitinibinpatientswithactiverheumatoidarthritisthedynamicsofpainandcentralsensitizationelements AT nalapkina veryearlyclinicalresponsetotreatmentwiththejanuskinaseinhibitortofacitinibinpatientswithactiverheumatoidarthritisthedynamicsofpainandcentralsensitizationelements AT gvlukina veryearlyclinicalresponsetotreatmentwiththejanuskinaseinhibitortofacitinibinpatientswithactiverheumatoidarthritisthedynamicsofpainandcentralsensitizationelements AT nakiryukhina veryearlyclinicalresponsetotreatmentwiththejanuskinaseinhibitortofacitinibinpatientswithactiverheumatoidarthritisthedynamicsofpainandcentralsensitizationelements AT syudavidyan veryearlyclinicalresponsetotreatmentwiththejanuskinaseinhibitortofacitinibinpatientswithactiverheumatoidarthritisthedynamicsofpainandcentralsensitizationelements AT tssalnikova veryearlyclinicalresponsetotreatmentwiththejanuskinaseinhibitortofacitinibinpatientswithactiverheumatoidarthritisthedynamicsofpainandcentralsensitizationelements AT rrsamigullina veryearlyclinicalresponsetotreatmentwiththejanuskinaseinhibitortofacitinibinpatientswithactiverheumatoidarthritisthedynamicsofpainandcentralsensitizationelements AT dschakieva veryearlyclinicalresponsetotreatmentwiththejanuskinaseinhibitortofacitinibinpatientswithactiverheumatoidarthritisthedynamicsofpainandcentralsensitizationelements AT immarusenko veryearlyclinicalresponsetotreatmentwiththejanuskinaseinhibitortofacitinibinpatientswithactiverheumatoidarthritisthedynamicsofpainandcentralsensitizationelements AT ovsemagina veryearlyclinicalresponsetotreatmentwiththejanuskinaseinhibitortofacitinibinpatientswithactiverheumatoidarthritisthedynamicsofpainandcentralsensitizationelements AT myusemchenkova veryearlyclinicalresponsetotreatmentwiththejanuskinaseinhibitortofacitinibinpatientswithactiverheumatoidarthritisthedynamicsofpainandcentralsensitizationelements AT afdavydova veryearlyclinicalresponsetotreatmentwiththejanuskinaseinhibitortofacitinibinpatientswithactiverheumatoidarthritisthedynamicsofpainandcentralsensitizationelements AT evkalinina veryearlyclinicalresponsetotreatmentwiththejanuskinaseinhibitortofacitinibinpatientswithactiverheumatoidarthritisthedynamicsofpainandcentralsensitizationelements |